These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 38325629

  • 1. Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study.
    Lin YH, Lin CH, Lin YC, Huang YY, Tai AS, Fu SC, Lin SH.
    Endocr Pract; 2024 May; 30(5):424-430. PubMed ID: 38325629
    [Abstract] [Full Text] [Related]

  • 2. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
    Lyu B, Grams ME, Chang A, Inker LA, Coresh J, Shin JI.
    Am J Cardiol; 2022 Feb 15; 165():124-130. PubMed ID: 34937658
    [Abstract] [Full Text] [Related]

  • 3. Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis.
    Du Y, Bai L, Fan B, Ding H, Ding H, Hou L, Ma H, Xing N, Wang F.
    Prim Care Diabetes; 2022 Feb 15; 16(1):156-161. PubMed ID: 34930687
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.
    Barkmeier AJ, Herrin J, Swarna KS, Deng Y, Polley EC, Umpierrez GE, Galindo RJ, Ross JS, Mickelson MM, McCoy RG.
    Ophthalmol Retina; 2024 Oct 15; 8(10):943-952. PubMed ID: 38735641
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N.
    Circulation; 2018 Apr 03; 137(14):1450-1459. PubMed ID: 29133607
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
    Lee HF, Chen SW, Liu JR, Li PR, Wu LS, Chang SH, Yeh YH, Kuo CT, Chan YH, See LC.
    Cardiovasc Diabetol; 2020 Sep 30; 19(1):160. PubMed ID: 32998736
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.
    Circulation; 2019 Apr 23; 139(17):2022-2031. PubMed ID: 30786725
    [Abstract] [Full Text] [Related]

  • 12. SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation.
    Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Yeh YH, Kuo CT, See LC, Lip GYH.
    J Clin Endocrinol Metab; 2024 Sep 16; 109(10):2617-2629. PubMed ID: 38466894
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J, Bates BA, Setoguchi S, Gerhard T, Dave CV.
    Cardiovasc Diabetol; 2023 Mar 10; 22(1):54. PubMed ID: 36899387
    [Abstract] [Full Text] [Related]

  • 14. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY, Yang CT, Kuo S, Wu CH, Lin WH, Ou HT.
    JAMA Netw Open; 2022 Dec 01; 5(12):e2246928. PubMed ID: 36520437
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG, Van Houten HK, Deng Y, Mandic PK, Ross JS, Montori VM, Shah ND.
    JAMA Netw Open; 2021 Feb 01; 4(2):e2035792. PubMed ID: 33523188
    [Abstract] [Full Text] [Related]

  • 16. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.
    Pinto LC, Rados DV, Remonti LR, Viana LV, Pulz GT, Carpena MP, Borges RP, Marobin R, Beretta MV, Pedrollo EF, Londero TM, Machry R, Janeczko L, Moehlecke M, Falcetta MR, Bauer AC, Silveiro SP, Gerchman F, Rodrigues TC, Kramer CK, Bertoluci MC, Leitão CB.
    J Clin Endocrinol Metab; 2020 Nov 01; 105(11):. PubMed ID: 32797182
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK, Smith SM, Park H.
    Cardiovasc Diabetol; 2018 Jul 17; 17(1):102. PubMed ID: 30016946
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 Jul 17; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.